Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Investigating the relationship between IGF-I, -II and IGFBP-3 concentrations and later-life cognition and brain volume

View ORCID ProfileAntoine Salzmann, View ORCID ProfileSarah-Naomi James, View ORCID ProfileDylan M. Williams, View ORCID ProfileMarcus Richards, View ORCID ProfileDorina Cadar, View ORCID ProfileJonathan M. Schott, View ORCID ProfileWilliam Coath, View ORCID ProfileCarole H. Sudre, View ORCID ProfileNishi Chaturvedi, View ORCID ProfileVictoria Garfield
doi: https://doi.org/10.1101/2020.10.09.20209833
Antoine Salzmann
1MRC Unit for Lifelong Health and Ageing at UCL, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Antoine Salzmann
  • For correspondence: antoine.salzmann.14@ucl.ac.uk
Sarah-Naomi James
1MRC Unit for Lifelong Health and Ageing at UCL, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sarah-Naomi James
Dylan M. Williams
1MRC Unit for Lifelong Health and Ageing at UCL, University College London, London, UK
2Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dylan M. Williams
Marcus Richards
1MRC Unit for Lifelong Health and Ageing at UCL, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marcus Richards
Dorina Cadar
3Department of Behavioural Science and Health, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dorina Cadar
Jonathan M. Schott
4Department of Neurodegenerative Disease, The Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jonathan M. Schott
William Coath
4Department of Neurodegenerative Disease, The Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for William Coath
Carole H. Sudre
4Department of Neurodegenerative Disease, The Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK
5School of Biomedical Engineering and Imaging Sciences, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Carole H. Sudre
Nishi Chaturvedi
1MRC Unit for Lifelong Health and Ageing at UCL, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nishi Chaturvedi
Victoria Garfield
1MRC Unit for Lifelong Health and Ageing at UCL, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Victoria Garfield
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background The insulin/insulin-like signalling (IIS) pathways, including Insulin-like Growth Factors (IGFs), varies with age. However, their association with late-life cognition and neuroimaging parameters is not well characterised.

Methods Using data from the British 1946 birth cohort we investigated associations of IGF-I, -II and IGFBP-3 (measured at 53 and 60-64 years) with cognitive performance (word learning test (WLT) and visual letter search (VLS) – at 60-64y and 69y) and cognitive state (Addenbrooke’s Cognitive Exam-III (ACE-III) - at 69-71y), and in a proportion, quantified neuroimaging measures (whole brain volume (WBV); white matter hyperintensity volume (WMHV); hippocampal volume (HV)). Regression models included adjustments for demographic, lifestyle and health factors.

Results Higher IGF-I and IGF-II at 53y was associated with higher ACE-III scores (ß 0.07 95%CI [0.02,0.12]; scoreACE-III 89.48 [88.86,90.1], respectively). IGF-II at age 53y was additionally associated with higher WLT scores (scoreWLT 20 [19.35,20.65]). IGFBP-3 at 60-64y was associated with favourable VLS score at 60-64y and 69y (ß 0.07 [0.01,0.12]; ß 0.07 [0.02,0.12], respectively), higher memory and cognitive state at 69y (ß 0.07 [0.01,0.12]; ß 0.07 [0.01,0.13], respectively) and reduced WMHV (ß -0.1, [-0.21,-0.00]). IGF-I/IGFBP-3 at 60-64y was associated with lower VLS scores at 69y (ß -0.08, [-0.15,-0.02]).

Conclusions Increased measure in IIS parameters (IGF-I, -II and IGFBP-3) relate to better cognitive state in later life. There were apparent associations with specific cognitive domains (IGF-II relating to memory; IGFBP-3 to memory, processing speed and WMHV; and IGF-I/IGFBP-3 molar ratio with slower processing speed). IGFs and IGFBP-3 are associated with favourable cognitive function outcomes.

Competing Interest Statement

JMS has received research funding from Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly), has consulted for Roche Pharmaceuticals, Biogen, and Eli Lilly, given educational lectures sponsored by GE, Eli Lilly and Biogen, and serves on a Data Safety Monitoring Committee for Axon Neuroscience SE. NC receives funds for serving on a Data Safety Monitoring Committee for a study sponsored by AstraZeneca. All other authors have no conflicts of interest to declare.

Funding Statement

This work was supported by the UK Medical Research Council,which provides core funding for the MRC Unit For Lifelong Health and Ageing at UCL and the MRC National Survey of Health and Development (MC_UU_00019/1) and supports AS, NC, DW, MR, SNJ (MC_ST_LHA_2019; MC_UU_0019/2, MC_UU_0019/3). Insight 46 is principally funded by grants from Alzheimer's Research UK (and SNJ ARUK-PG2014-1946, ARUK-PG2017-1946), the Medical Research Council Dementias Platform UK (CSUB19166), the Wolfson Foundation (PR/ylr/18575) and The Drake Foundation. JMS acknowledges the EPSRC (EP/J020990/1) and European Union's Horizon 2020 research and innovation programme (Grant 666992) and a Weston Brain Institute and Selfridges Group Foundation award (176724). DC is funded by the National Institute on Aging (RO1AG017644) and ESRC (ES/S013830/1). CHS is supported by an Alzheimer's Society Junior Fellowship (AS-JF-17-011). VG is funded by Joint Diabetes UK and British Heart Foundation (15/0005250).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

MRC

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • FUNDING: This work was supported by the UK Medical Research Council,which provides core funding for the MRC Unit For Lifelong Health and Ageing at UCL and the MRC National Survey of Health and Development (MC_UU_00019/1) and supports AS, NC, DW, MR, SNJ (MC_ST_LHA_2019; MC_UU_0019/2, MC_UU_0019/3). Insight 46 is principally funded by grants from Alzheimer’s Research UK (and SNJ ARUK-PG2014-1946, ARUK-PG2017-1946), the Medical Research Council Dementias Platform UK (CSUB19166), the Wolfson Foundation (PR/ylr/18575) and The Drake Foundation. JMS acknowledges the EPSRC (EP/J020990/1) and European Union’s Horizon 2020 research and innovation programme (Grant 666992) and a Weston Brain Institute and Selfridges Group Foundation award (176724). DC is funded by the National Institute on Aging (RO1AG017644) and ESRC (ES/S013830/1). CHS is supported by an Alzheimer’s Society Junior Fellowship (AS-JF-17- 011). VG is funded by Joint Diabetes UK and British Heart Foundation (15/0005250).

  • DISCLOSURE: JMS has received research funding from Avid Radiopharmaceuticals (a wholly-owned subsidiary of Eli Lilly), has consulted for Roche Pharmaceuticals, Biogen, and Eli Lilly, given educational lectures sponsored by GE, Eli Lilly and Biogen, and serves on a Data Safety Monitoring Committee for Axon Neuroscience SE. NC receives funds for serving on a Data Safety Monitoring Committee for a study sponsored by AstraZeneca. All other authors have no conflicts of interest to declare.

Data Availability

Restrictions apply to the availability of some or all data generated or analyzed during this study to preserve patient confidentiality or because they were used under license. The corresponding author will on request detail the restrictions and any conditions under which access to some data may be provided.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted February 23, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Investigating the relationship between IGF-I, -II and IGFBP-3 concentrations and later-life cognition and brain volume
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Investigating the relationship between IGF-I, -II and IGFBP-3 concentrations and later-life cognition and brain volume
Antoine Salzmann, Sarah-Naomi James, Dylan M. Williams, Marcus Richards, Dorina Cadar, Jonathan M. Schott, William Coath, Carole H. Sudre, Nishi Chaturvedi, Victoria Garfield
medRxiv 2020.10.09.20209833; doi: https://doi.org/10.1101/2020.10.09.20209833
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Investigating the relationship between IGF-I, -II and IGFBP-3 concentrations and later-life cognition and brain volume
Antoine Salzmann, Sarah-Naomi James, Dylan M. Williams, Marcus Richards, Dorina Cadar, Jonathan M. Schott, William Coath, Carole H. Sudre, Nishi Chaturvedi, Victoria Garfield
medRxiv 2020.10.09.20209833; doi: https://doi.org/10.1101/2020.10.09.20209833

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (230)
  • Allergy and Immunology (507)
  • Anesthesia (111)
  • Cardiovascular Medicine (1254)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (283)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (537)
  • Epidemiology (10043)
  • Forensic Medicine (5)
  • Gastroenterology (500)
  • Genetic and Genomic Medicine (2477)
  • Geriatric Medicine (239)
  • Health Economics (482)
  • Health Informatics (1650)
  • Health Policy (756)
  • Health Systems and Quality Improvement (638)
  • Hematology (250)
  • HIV/AIDS (536)
  • Infectious Diseases (except HIV/AIDS) (11886)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (255)
  • Medical Ethics (75)
  • Nephrology (269)
  • Neurology (2298)
  • Nursing (140)
  • Nutrition (354)
  • Obstetrics and Gynecology (458)
  • Occupational and Environmental Health (537)
  • Oncology (1255)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (326)
  • Pediatrics (736)
  • Pharmacology and Therapeutics (315)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2291)
  • Public and Global Health (4849)
  • Radiology and Imaging (844)
  • Rehabilitation Medicine and Physical Therapy (493)
  • Respiratory Medicine (654)
  • Rheumatology (288)
  • Sexual and Reproductive Health (241)
  • Sports Medicine (227)
  • Surgery (271)
  • Toxicology (44)
  • Transplantation (130)
  • Urology (100)